Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab in NASH Cirrhosis
NCT01672879Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2012
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of simtuzumab in Liver cirrhosis (LC) and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Change From Baseline in Hepatic Venous Pressure Gradient at Week 96 and Event-Free Survival up to 240 weeks. Started Oct 2012; status: terminated.
02
Drugs
simtuzumab
03
Conditions
Liver cirrhosis (LC)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01672879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01672879.